G Zalcman Selected Research

G Zalcman Research Topics

Disease

16	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2022 - 01/2004
15	Neoplasms (Cancer) 09/2021 - 01/2000
11	Lung Neoplasms (Lung Cancer) 01/2021 - 01/2000
4	Mesothelioma 12/2016 - 09/2006
4	Neoplasm Metastasis (Metastasis) 10/2016 - 01/2007
3	Malignant Mesothelioma 01/2022 - 10/2007
2	Pneumonia (Pneumonitis) 01/2018 - 01/2016
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 05/2015 - 01/2000
2	Adenocarcinoma 10/2007 - 11/2004
1	Brain Neoplasms (Brain Tumor) 01/2022
1	COVID-19 09/2021
1	Cytokine Release Syndrome 09/2021
1	Infections 09/2021
1	Xanthogranulomatous Pyelonephritis 04/2018
1	Urinary Tract Infections (Urinary Tract Infection) 01/2018
1	Dysbiosis 01/2018
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 05/2017
1	Hypertension (High Blood Pressure) 05/2017
1	Diarrhea 05/2017
1	Carcinoma (Carcinomatosis) 01/2016
1	Bronchiolitis 01/2016
1	Organizing Pneumonia 01/2016
1	Tuberculosis (Tuberculoses) 08/2014
1	Extensively Drug-Resistant Tuberculosis 08/2014
1	Adenocarcinoma of Lung 10/2007
1	Cardiovascular Diseases (Cardiovascular Disease) 02/2007
1	Mucinous Adenocarcinoma (Mucinous Carcinoma) 02/2007
1	Carcinoid Tumor (Carcinoid) 01/2007
1	Pulmonary Atelectasis 01/2007
1	Thoracic Diseases 01/2007
1	Carcinogenesis 11/2006
1	Bronchogenic Carcinoma 11/2006

Drug/Important Bio-Agent (IBA)

5	Immune Checkpoint InhibitorsIBA 09/2021 - 01/2016
4	Pemetrexed (MTA)FDA Link 09/2022 - 10/2007
4	Cisplatin (Platino)FDA LinkGeneric 09/2022 - 02/2007
3	Cetuximab (Erbitux)FDA Link 09/2022 - 10/2008
3	Bevacizumab (Avastin)FDA Link 05/2015 - 02/2007
3	Biological ProductsIBA 10/2008 - 11/2006
2	NivolumabIBA 01/2022 - 01/2016
2	CrizotinibIBA 12/2019 - 04/2018
2	Monoclonal AntibodiesIBA 11/2018 - 10/2008
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2018 - 08/2014
2	Tyrosine Kinase InhibitorsIBA 06/2011 - 11/2006
2	PlatinumIBA 04/2011 - 01/2004
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2007 - 11/2006
2	AntibodiesIBA 01/2001 - 01/2000
1	IpilimumabIBA 01/2022
1	lorlatinibIBA 01/2022
1	Messenger RNA (mRNA)IBA 09/2021
1	VaccinesIBA 09/2021
1	Anaplastic Lymphoma KinaseIBA 12/2019
1	LigandsIBA 11/2018
1	durvalumabIBA 11/2018
1	LactamsIBA 01/2018
1	QuinolonesIBA 01/2018
1	Transaminases (Aminotransferases)IBA 05/2017
1	Focal Adhesion Protein-Tyrosine KinasesIBA 12/2016
1	Neurofibromin 2 (Merlin)IBA 12/2016
1	GSK2256098IBA 12/2016
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2016
1	SteroidsIBA 01/2016
1	Gemcitabine FDA Link 11/2014
1	iniparibIBA 11/2014
1	Pharmaceutical PreparationsIBA 08/2014
1	ErbB Receptors (EGF Receptor)IBA 01/2011
1	AsbestosIBA 10/2007
1	pentetreotide (OctreoScan)FDA Link 01/2007
1	Platinum Compounds (Compounds, Platinum)IBA 11/2006
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2006
1	TubulinIBA 11/2006
1	Gefitinib (Iressa)FDA Link 11/2004
1	Docetaxel (Taxotere)FDA Link 01/2004
1	Biomarkers (Surrogate Marker)IBA 10/2002
1	Tumor Protein p73IBA 01/2001

Therapy/Procedure

12	Drug Therapy (Chemotherapy) 01/2022 - 01/2004
8	Therapeutics 01/2019 - 11/2006
5	Radiotherapy 09/2022 - 09/2006
3	Biological Therapy 11/2006 - 10/2002
2	Immunotherapy 01/2019 - 01/2016
1	Injections 09/2021
1	Time-to-Treatment 01/2021
1	Induction Chemotherapy 05/2015
1	Collapse Therapy 08/2014
1	Adjuvant Chemotherapy 09/2006